AQR Capital Management
NGNE icon

AQR Capital Management’s Neurogene NGNE Stock Holding History

AQR Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$474K Buy
15,061
+4,750
+46% +$131K ﹤0.01% 3413
2026
Q1 		$208K Buy
+10,311
New +$200K ﹤0.01% 3587
2021
Q1 		– Sell
-1,188
Closed -$335K – 2245
2020
Q4 		$335K Sell
1,188
-252
-18% -$61.6K ﹤0.01% 1927
2020
Q3 		$346K Buy
+1,440
New +$349K ﹤0.01% 1869

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

AQR Capital Management's NGNE Position: Q2 2026 in Review

AQR Capital Management increased its Neurogene (NGNE) stake by 46% in Q2 2026, buying an estimated $131K and bringing the position to 15,061 shares worth $474K. The position accounts for ﹤0.01% of the portfolio, ranked #3413.

AQR Capital Management first reported a position in NGNE in Q3 2020 and has held it in 4 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • AQR Capital Management held 15,061 shares of Neurogene worth $474K as of Q2 2026.
  • AQR Capital Management bought 4,750 Neurogene shares in Q2 2026, an estimated $131K.
  • Neurogene made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3413 holding.
  • AQR Capital Management first reported a position in Neurogene in Q3 2020 and has held it in 4 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.